BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2014 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

This survey of US primary care physicians (n=10) and endocrinologists (n=10) was undertaken to evaluate the impact of GLP-1 agonists if they were to be introduced in the Diabetes market.

While NVO’s Victoza, injected daily, has become a blockbuster, GLP-1 agonists are still only prescribed in a limited percentage of patients. Weekly GLP-1 agonists have suffered from inconvenient delivery, including needle size and need for premixing, and have lagged Victoza on some measures in head-to-head trials. Weekly Bydureon did just have a pen device approved, though it is fairly inconvenient to use. But the field is changing. Weekly dulaglutide (LLY), which has a more convenient device, has a PDUFA later this year. Details from dulaglutide’s study against Victoza were released at the ADA meeting earlier this year and subsequently published, showing comparability on most efficacy and safety measures, though it lagged slightly on weight loss. ITCA-650, an exenatide mini-pump that only needs to be exchanged every 6 months or a year is a wild card currently in Phase III trials. Weekly exenatide suspension, a more convenient formulation of Bydureon, is expected to have data at the EASD in September. GLP-1 agonist/basal insulin fixed dose combinations could also have an impact.

To purchase the GLP-1 Pulse Survey, click the link at the top of the page.

For our disclosures, please read the BioMedTracker Research Standards.